REPORT ID 6606

EMEA (Europe, Middle East and Africa) Human Vaccines Market Report 2017

Publish Date
26-Dec-17
Pages
115
Format
Electronic (PDF)

In this report, the EMEA Human Vaccines market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (), revenue (Million USD), market share and growth rate of Human Vaccines for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Human Vaccines market competition by top manufacturers/players, with Human Vaccines sales volume (), price (), revenue (Million USD) and market share for each manufacturer/player; the top players including
    AstraZeneca
    Bavarian Nordic
    Bharat Biotech
    CSL Limited
    Emergent BioSolutions, Inc.
    GlaxoSmithKline plc
    Johnson & Johnson
    Merck & Co., Inc.
    Mymetics
    Novartis AG
    Pfizer, Inc.
    Sanofi
    Shenzhen Kangtai Biological Products Co., Ltd.
    Takeda Pharmaceutical Company Limited.

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Pneumococcal
    Influenza
    Hepatitis
    HPV
    Meningococcal
    Rotavirus
    Measles
    Typhoid
    Combination

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Pediatrics
    Adolescents
    Adults
    Geriatrics

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Human Vaccines Market Report 2017
1 Human Vaccines Overview
    1.1 Product Overview and Scope of Human Vaccines
    1.2 Classification of Human Vaccines
        1.2.1 EMEA Human Vaccines Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Human Vaccines Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Pneumococcal
        1.2.4 Influenza
        1.2.5 Hepatitis
        1.2.6 HPV
        1.2.7 Meningococcal
        1.2.8 Rotavirus
        1.2.9 Measles
        1.2.10 Typhoid
        1.2.11 Combination
    1.3 EMEA Human Vaccines Market by Application/End Users
        1.3.1 EMEA Human Vaccines Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Pediatrics
        1.3.3 Adolescents
        1.3.4 Adults
        1.3.5 Geriatrics
    1.4 EMEA Human Vaccines Market by Region
        1.4.1 EMEA Human Vaccines Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Human Vaccines (2012-2022)
        1.5.1 EMEA Human Vaccines Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Human Vaccines Revenue and Growth Rate (2012-2022)

2 EMEA Human Vaccines Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Human Vaccines Market Competition by Players/Manufacturers
        2.1.1 EMEA Human Vaccines Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Human Vaccines Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Human Vaccines Sale Price by Players (2012-2017)
    2.2 EMEA Human Vaccines (Volume and Value) by Type/Product Category
        2.2.1 EMEA Human Vaccines Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Human Vaccines Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Human Vaccines Sale Price by Type (2012-2017)
    2.3 EMEA Human Vaccines (Volume) by Application
    2.4 EMEA Human Vaccines (Volume and Value) by Region
        2.4.1 EMEA Human Vaccines Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Human Vaccines Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Human Vaccines Sales Price by Region (2012-2017)

3 Europe Human Vaccines (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Human Vaccines Sales and Value (2012-2017)
        3.1.1 Europe Human Vaccines Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Human Vaccines Revenue and Growth Rate (2012-2017)
    3.2 Europe Human Vaccines Sales and Market Share by Type
    3.3 Europe Human Vaccines Sales and Market Share by Application
    3.4 Europe Human Vaccines Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Human Vaccines Sales Volume by Countries (2012-2017)
        3.4.2 Europe Human Vaccines Revenue by Countries (2012-2017)
        3.4.3 Germany Human Vaccines Sales and Growth Rate (2012-2017)
        3.4.4 France Human Vaccines Sales and Growth Rate (2012-2017)
        3.4.5 UK Human Vaccines Sales and Growth Rate (2012-2017)
        3.4.6 Russia Human Vaccines Sales and Growth Rate (2012-2017)
        3.4.7 Italy Human Vaccines Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Human Vaccines Sales and Growth Rate (2012-2017)

4 Middle East Human Vaccines (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Human Vaccines Sales and Value (2012-2017)
        4.1.1 Middle East Human Vaccines Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Human Vaccines Revenue and Growth Rate (2012-2017)
    4.2 Middle East Human Vaccines Sales and Market Share by Type
    4.3 Middle East Human Vaccines Sales and Market Share by Application
    4.4 Middle East Human Vaccines Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Human Vaccines Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Human Vaccines Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Human Vaccines Sales and Growth Rate (2012-2017)
        4.4.4 Israel Human Vaccines Sales and Growth Rate (2012-2017)
        4.4.5 UAE Human Vaccines Sales and Growth Rate (2012-2017)
        4.4.6 Iran Human Vaccines Sales and Growth Rate (2012-2017)

5 Africa Human Vaccines (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Human Vaccines Sales and Value (2012-2017)
        5.1.1 Africa Human Vaccines Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Human Vaccines Revenue and Growth Rate (2012-2017)
    5.2 Africa Human Vaccines Sales and Market Share by Type
    5.3 Africa Human Vaccines Sales and Market Share by Application
    5.4 Africa Human Vaccines Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Human Vaccines Sales Volume by Countries (2012-2017)
        5.4.2 Africa Human Vaccines Revenue by Countries (2012-2017)
        5.4.3 South Africa Human Vaccines Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Human Vaccines Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Human Vaccines Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Human Vaccines Sales and Growth Rate (2012-2017)

6 EMEA Human Vaccines Manufacturers/Players Profiles and Sales Data
    6.1 AstraZeneca
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Human Vaccines Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 AstraZeneca Human Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Bavarian Nordic
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Human Vaccines Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Bavarian Nordic Human Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Bharat Biotech
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Human Vaccines Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Bharat Biotech Human Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 CSL Limited
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Human Vaccines Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 CSL Limited Human Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Emergent BioSolutions, Inc.
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Human Vaccines Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Emergent BioSolutions, Inc. Human Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 GlaxoSmithKline plc
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Human Vaccines Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 GlaxoSmithKline plc Human Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Johnson & Johnson
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Human Vaccines Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Johnson & Johnson Human Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Merck & Co., Inc.
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Human Vaccines Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Merck & Co., Inc. Human Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Mymetics
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Human Vaccines Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Mymetics Human Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Novartis AG
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Human Vaccines Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Novartis AG Human Vaccines Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Pfizer, Inc.
    6.12 Sanofi
    6.13 Shenzhen Kangtai Biological Products Co., Ltd.
    6.14 Takeda Pharmaceutical Company Limited.

7 Human Vaccines Manufacturing Cost Analysis
    7.1 Human Vaccines Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Human Vaccines

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Human Vaccines Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Human Vaccines Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Human Vaccines Market Forecast (2017-2022)
    11.1 EMEA Human Vaccines Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Human Vaccines Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Human Vaccines Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Human Vaccines Price and Trend Forecast (2017-2022)
    11.2 EMEA Human Vaccines Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Human Vaccines Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Human Vaccines Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Human Vaccines Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Human Vaccines Sales Forecast by Type (2017-2022)
    11.7 EMEA Human Vaccines Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer